Product Name: LATS1 (1106-1124)
Product Number: PE-01BDM99
Size: 200 µg      Price:64.00
1 mg      $US128.00
5 mg      280.00
Peptide Name: LATS1 (1106-1124)

Product Use: Services as a blocking peptide for use with the LATS1-CT rabbit polyclonal antibody (Cat. No.: AB-NK091-2) that is also available from Kinexus. The peptide sequence is located in the C-terminus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CGSEQQSDEDDQNTGSEIKN

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 2183.1 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: LATS1 pan-specific antibody (Cat. No.: AB-NK091-2)

Scientific Background: LATS1 (WARTS) is a protein-serine/threonine kinase of the AGC group and NDR family. LATS1 appears to be a tumour suppressor protein (TSP), although it undergoes a typical rate of bystander mutations in human cancers. The active form of the protein kinase normally acts to inhibit tumour cell proliferation. It also promotes apoptosis by activating the transcription of BAX, caspase 3 and p53, and inhibiting the oncogene actions of YAP1. It can phosphorylate and inactivate the YAP1 and inhibit its translocation to the nucleus for transcription of genes important for proliferation and migration. NUAK1 and NUAK2 mediated phosphorylation of LATS1 can be inhibited with a LATS1 mutation of S464A. Inhibition of LATS1-YAP1 interaction can occur with a Y559F mutation. The K734A mutation can abrogate kinase phosphotransferase activity, lack of p53 translation, increased time for mitosis, autophosphorylation, and increased ploidy. LATS1 also negatively regulates the G2/M transition by downregulating CDK1 phosphotransferase activity. M669I and R806P mutations have been associated with lung adenocarcinoma and lung large cell carcinoma, respectively. Decreased LATS1 expression due to hypermethylation of the promoter have been associated with breast cancer, acute lymphoblastic leukemia, ovarian cancer, and astrocytoma. However, the very low frequency of reported somatic mutations in this protein indicates that it may function as a tumour requiring protein (TRP) in many human tumours. LATS1 is activated by phosphorylation at S909 and T1079.